AIDD is an integrated tool and a radically new way to discovery new drugs for neurodegenerative diseases (Alzheimer’s, Epilepsy, Ageing, etc.).
Technologies
In this section it is possible to view, also through targeted research, the technologies inserted in the PROMO-TT Database. For further information on the technologies and to contact the CNR Research Teams who developed them, it is necessary to contact the Project Manager (see the references at the bottom of each record card).
Displaying results 1 - 6 of 6
The final technology will add polarimetric capability to imaging cameras in the NUV/optical, providing simultaneous measurements of the different polarization states of the light. This will be obtained by the development of an innovative coating based on nanostructured emissive materials sensitive to the polarization of the incident light. A double layer film of two organic systems will be coupled to image detectors so that the two polarization components of the incoming light are converted into two different colors.
At IFN-CNR, in collaboration with Politecnico di Milano-Department of Physics, we have developed Raman microscopy approaches compatible with the study and characterization of biological and industrial samples. In detail, our facility houses a self-built spontaneous confocal Raman microscope with the following characteristics: two excitation lasers (660nm and 785nm), inverted microscope (Olympus IX-73) and Princeton spectrometer / CCD.
Mergers e Acquisitions represent important forms of business deals because of the volumes involved in the transactions and the role of the innovation activity of companies. By considering the patent activity of about one thousand companies, we develop a method to predict future acquisitions by assuming that companies deal more frequently with technologically related ones.
This is a high-throughput sequencing based method to map euchromatin and heterochromatin accessibility. The method is based on the sequential extraction of distinct nuclear fractions containing: soluble proteins (S1 fraction); the surnatant obtained after DNase treatment (S2 fraction); DNase-resistant chromatin extracted with high salt buffer (S3 fraction); and the most condensed and insoluble portion of chromatin, extracted with urea buffer that solubilizes the remaining proteins and membranes (S4 fraction).
Safe, efficient and specific nano-delivery systems are increasingly needed for precision and regenerative medicine and targeted therapies (e.g. anticancer and antimicrobial therapies), as well as for the cosmetic and nutraceutical sectors’ applications. Despite the appreciable success of synthetic nanovectors, like for example liposomes, their clinical and market application is hampered by some limitations: • large scale production, • low cost production • intrinsic toxicity • limited cellular uptake • limited consumer acceptance.